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In most patients with cystic fibrosis (CF) life expectancy is limited due to a progressive loss of functional lung tissue. Already very early
in life a persistent neutrophylic inflammation can be demonstrated in the airways. The cause of this inflammation, the role of CFTR and
different CF specific bacteria like Pseudomonas aeruginosa are not well understood. This short review summarises the current understanding
and hypothesis of the origin of this complicated process of inflammation and infection. Better understanding of this process may lead to the
development of new treatment modalities of CF lung disease and consequent improvement of life expectancy.
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Cystic Fibrosis (CF) is an autosomal recessive disorder
with a potential lethal outcome among white populations,
affecting approximately 1:3300 live white births [1]. CF is
caused by mutations in a single gene on chromosome 7
that encodes the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) [2]. These mutations cause
disruption of CFTR function within epithelial cells [3].
Although many organs are affected in CF, lung disease is
the major cause of morbidity and virtually all mortality.
The lungs, including mucus glands, are structurally normal
at birth [4]. Soon after birth excessive endobronchial
inflammation in the small airways has been demonstrated
in both sputum culture positive and sputum culture
negative patients. Broncho-alveolar lavage (BAL) fluid
shows a predominantly neutrophil inflammation with
elevated interleukin(IL)-8 and neutrophil elastase [5–8].
This persistent inflammation is the major cause of
progressive lung injury and destruction leading to a
decrease in lung function. This progressive loss of lung
function is the main reason for the limited life expectancy1569-1993/$ - see front matter D 2005 Published by Elsevier B.V. on behalf of E
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ology of lung inflammation and thereby the pathogenesis
of lung disease in CF is needed to improve current and
develop future treatment modalities.2. Defective CFTR and initiation of lung infection and
inflammation
Because inflammation has been demonstrated in culture
negative patients it has been postulated that, apart from
infection, defective CFTR itself may play an important role
in the excessive inflammation in the airways. As foetal CF
lungs are not grossly impaired as demonstrated by
histopathological studies, CFTR appears not to cause
inflammation in the lungs before birth. This is in sharp
contrast with other organs like the vas deferens, intestine
and pancreas that can be severely impaired during gestation.
Therefore it is doubtful that CFTR alone is responsible for
the initiation of lung inflammation with consequent tissue
destruction. Most likely, the observation that excessive
inflammation is present in patients with negative cultures
may be due to the regional variability of inflammation and
infection in different parts of the lung [8]. Another
explanation may be that bacteria below detectable levels
are responsible for lung inflammation.is 4 (2005) 3 – 5uropean Cystic Fibrosis Society.
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initiates inflammation, it may enhance or contribute to the
inflammatory response to infection. Two hypothesis have
been proposed that may contribute to the initiation of
infection and inflammation in CF.
2.1. The salt depletion hypothesis
In this hypothesis the airways may be compared to sweat
glands. The epithelial cells of the airways regulate the salt
concentration in the airway surface liquid (ASL). Due to
defective CFTR salt concentrations in the ASL are elevated.
The function of innate antimicrobial peptide defensins is
critically dependent on the ASL salt concentration.
In vitro it has been shown that defensins are inactivated
by salt concentrations higher than 50 mmol/L thereby
facilitating infection and bacterial growth [9].
2.2. The isotonic low volume hypothesis
In this hypothesis water permeable airway epithelia
regulate the volume of the ASL.
Abnormal sodium absorption together with defective
CFTR with consequent failure to secrete chloride leads to
water and volume depletion of the ASL in an isotonic
environment. Volume and water depletion occurs in the ASL
and the periciliary fluid leading to increased viscosity in
both compartments and consequent impaired mucociliary
clearance. Bacteria are trapped in the tenacious mucus layer
and consequently lead to chronic infection [10,11].3. CFTR and Pseudomonas aeruginosa
Initiation of (chronic) infection can probably be
explained by the qualitative changes in the ASL as has
been described above. This does however not explain why
patients with CF are infected with specific micro-organisms,
especially P. aeruginosa.
There are a number of hypothesis that try to explain the
unfavourable relationship between CF and P. aeruginosa.
3.1. CFTR may act as a specific receptor for P. aeruginosa
CFTR, apart from its function as a chloride ion channel,
appears to act as a receptor for epithelial cell internalisation
of P. aeruginosa on the airway surface [12–14]. Therefore,
mutant CFTR results in reduced binding of P. aeruginosa
and consequent reduction of P. aeruginosa clearance from
the airways of patients with CF.
3.2. CFTR may influence bacterial adherence to epithelial
cells
Epithelial cells of CF airways demonstrate a greater
adherence to piliated strains of P. aeruginosa [15–17].Expression of wild type CFTR in CF cell lines reduces the
adherence of P. aeruginosa. Additionally, adherence of P.
aeruginosa is greater in cell lines from patients homozygous
for DF508 compared with heterozygotes and carriers [18].
The underlying process of this phenomomenon is not well
understood although an increase in asialogangliosde-1
receptors in CF epithelial cells may play a significant role.4. Bacteria and lung inflammation
Virtually all patients with CF are chronically infected
with one ore more bacterial species.
The inflammatory response to infection appears to be
more intense in patients with CF compared to non-CF
patients. Additionally, it has been shown that the number of
colony forming units in BAL fluid is directly related to the
intensity of the inflammatory response with a significant
increase in the number of inflammatory cells and an increase
in IL-8 concentrations [19].
Early infection of the CF airways is mostly caused by
Staphylococcus aureus and Haemophilus influenza [20].
Of more significance is chronic infection with P.
aeruginosa. When initial colonization/infection with non-
mucoid strains is not sufficiently treated, most patients
become chronically infected with mucoid strains of P.
aeruginosa. The prevalence of chronic infection with P.
aeruginosa increases with age and is accompanied by a
decrease in the prevalence of both H. influenza and S.
aureus [20]. Chronic infection is prevalent in about 80%
of all patients with CF. Recent studies, especially
following patients diagnosed by neonatal screening, have
shown that infection with P. aeruginosa occurs already at
very young age [21]. Positive antibody response to P.
aeruginosa was found in children with a mean age of 15
months, about 12 months before first cultures were
positive. Also in young, non-sputum producing children
it was found that throat swabs frequently showed positive
cultures for P. aeruginosa [22].
In chronic infection with alginate-coated mucoid strains
of P. aeruginosa, eradication is nearly impossible. Even
with intensive antibiotic regimens, mucoid P. aeruginosa
cannot be eradicated, probably because of poor penetration
of antibiotics into anaerobic sputum plugs and rapid
development of mutator strains, which show enhanced
resistance to antimicrobial drugs [23,24].
Acquisition and consequent chronic infection with
mucoid strains of P. aeruginosa leads to an increase in the
endobronchial inflammatory response to infection. It has
been shown that CF cell lines produce more pro-inflamma-
tory cytokines than normal cell lines in response to P.
aeruginosa [25]. This ‘‘overproduction’’ of pro-inflamma-
tory cytokines can be found in the ELF of CF airways [26].
Also significantly lower levels of the anti-inflammatory
cytokine IL-10 , which inhibits the production of pro-
inflammatory cytokines, are found. This imbalance of anti-
H. Heijerman / Journal of Cystic Fibrosis 4 (2005) 3–5 5inflammatory and pro-inflammatory cytokines results in an
excessive and persistent inflammation in the CF airways. As
a result lung function deteriorates more rapidly in P.
aeruginosa positive patients compared with CF patients
negative for P. aeruginosa [27,28].5. Conclusion
After being born with anatomically ‘‘normal’’ lungs,
patients with CF develop endobronchial inflammation at
very young age. This endobronchial inflammation is the
result of an overreaction of the immunological response to
infection which occurs due to CFTR related abnormalities in
the ASL. The unfavourable relation of CF airways with P.
aeruginosa results in chronic infection in the majority of
patients, often already at a very young age. Chronic
infection with P. aeruginosa further enhances the endo-
bronchial inflammatory response with an imbalance
between pro- and contra inflammatory mediators leading
to destruction of lung tissue and a decrease in pulmonary
function.
Better understanding of this process may offer new
treatment modalities directed at the prevention of chronic
infection with P. aeruginosa and an inhibition of the
inflammatory response.References
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